790-P: The Effect of Tirzepatide vs. Placebo on Changes and Shifts in BMI Category in Adults with Type 2 Diabetes—A Post Hoc Analysis of the SURMOUNT-2 Study

Tirzepatide (TZP) is a GIP and GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. The SURMOUNT-2 (SM-2) trial demonstrated significant reductions in body weight in participants treated with TZP with a BMI ≥27 kg/m² and T2D. This subgroup analysis explored changes in BMI during the SM-2 trial. Prespecified subgroup analyses were conducted on the mITT population in the SM-2 trial to assess the effects of weekly treatment (TZP 10 or 15 mg vs placebo (PBO)) on change from baseline in BMI category at week 72. Table shows shifts in BMI category from baseline to week 72. At Week 72, TZP 10 and 15 mg each resulted in statistically significant reductions in BMI from baseline versus PBO (-4.87 and -5.66 versus -1.18 kg/m² respectively, p<0.001). For TZP 10 mg and 15 mg arms, 64.7% and 69.5% of participants shift down at least one BMI category, versus 20.9% for PBO. A normal BMI (<25kg/m²) at endpoint was achieved by 18.0% of participants in the 15 mg, and 12.2% in the 10 mg TZP arm compared with 1.9% for PBO. The most common adverse reactions were GI across subgroups, consistent with the results of SM-2.

In conclusion, participants on TZP had significant mean reductions in BMI from baseline and a greater proportion of participants treated with TZP shifted to a lower BMI category compared with PBO.

View largeDownload slide

View largeDownload slide

Close modal